Filtered By:
Specialty: Pharmaceuticals
Infectious Disease: COVID-19
This page shows you your search results in order of date.
Order by Relevance | Date
Total 73 results found since Jan 2013.
COVID-19 Booster mRNA Dose Increases Antibody Duration
FRIDAY, Dec. 30, 2022 -- COVID-19 mRNA vaccine boosters increase antibody duration, but do not increase antibody levels, according to a study recently published in the Annals of Allergy, Asthma& Immunology.
Samuel M. Ailsworth, from the...
Source: Drugs.com - Pharma News - December 30, 2022 Category: Pharmaceuticals Source Type: news
Roche launches new diagnostic test for the better understanding of immune response to SARS-CoV-2
Elecsys IGRA SARS-CoV-2 testsupports the better understanding of immuneresponse to SARS-CoV-2 infection or vaccinationThe test detects T-cell response, which may play an important role in determining if immune protection has been achievedThenew diagnostic testmayprovide clinical care guidance, particularly forimmunocompromised and high-risk patient groupsBasel, 15 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys ® IGRA SARS-CoV-2 test in countries that accept the CE Mark1. The Elecsys IGRA SARS-CoV-2 test supports the better understanding of immune response to SARS-CoV-2 infection...
Source: Roche Investor Update - August 15, 2022 Category: Pharmaceuticals Source Type: news
Vaccine-induced immune response to omicron wanes substantially over time
Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substantially within 3 months, according to new clinical trial data. The findings, published today in Cell Reports Medicine, are from a study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The trial was led by NIAID's Infectious Diseases Clinical Research Consortium.
Source: World Pharma News - July 19, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
NIH launches clinical trial of mRNA Nipah virus vaccine
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an investigational vaccine to prevent infection with Nipah virus. The experimental vaccine is manufactured by Moderna, Inc., (Cambridge, Massachusetts) and was developed in collaboration with NIAID's Vaccine Research Center. It is based on a messenger RNA (mRNA) platform - a technology used in several approved COVID-19 vaccines.
Source: World Pharma News - July 11, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Fauci Has ' Rebound ' COVID After Paxlovid Treatment
THURSDAY, June 30, 2022 -- After being infected with COVID-19 earlier this month, Anthony Fauci, M.D., chief medical adviser to the president and director of the U.S. National Institute of Allergy and Infectious Diseases, experienced a rebound after...
Source: Drugs.com - Pharma News - June 30, 2022 Category: Pharmaceuticals Source Type: news
Fauci Tests Positive for COVID-19, Has Mild Symptoms
THURSDAY, June 16, 2022 -- Anthony Fauci, M.D., the country ' s leading infectious disease expert, has tested positive for COVID-19, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) announced Wednesday.
The 81-year-old director...
Source: Drugs.com - Pharma News - June 16, 2022 Category: Pharmaceuticals Source Type: news
Top Local Changemakers Addressing Health Equity Gaps Across the U.S. Named Johnson & Johnson Health Equity Innovation Challenge Awardees
NEW BRUNSWICK, N.J., June 14, 2022 – After an extensive search for the top changemakers in six key U.S. cities, Johnson & Johnson today announced the 14 awardees of its Health Equity Innovation Challenge. The awardees, who possess lived experience and a deep understanding of the communities they serve, were selected for their work in generating solutions to help close racial health and mortality gaps in six cities where Black and Brown individuals experience significant health inequities: Chicago, Detroit, Los Angeles, New Orleans, New York City and Philadelphia.The Health Equity Innovation Challenge was created by J...
Source: Johnson and Johnson - June 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Food Allergy Tied to Lower Risk for SARS-CoV-2 Infection
THURSDAY, June 9, 2022 -- Asthma is not associated with higher rates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or household transmission, but food allergy is associated with a lower risk, according to a study...
Source: Drugs.com - Pharma News - June 9, 2022 Category: Pharmaceuticals Source Type: news
Lack of Asthma Control More Likely With COVID-19-Related Anxiety
WEDNESDAY, May 11, 2022 -- Uncontrolled asthma is more likely among adults with asthma who have higher anxiety due to COVID-19, while most parents of children with food allergy (FA) reported unchanged or decreased FA-specific anxiety (FAA) due to...
Source: Drugs.com - Pharma News - May 11, 2022 Category: Pharmaceuticals Source Type: news
Rise in U.K. COVID-19 Cases Closely Watched by U.S. Health Officials
TUESDAY, March 15, 2022 -- The United States is keeping a close eye on rising COVID-19 cases and hospitalizations in Britain, Anthony Fauci, M.D., the director of the U.S. National Institute of Allergy and Infectious Diseases, said Tuesday.
Compared...
Source: Drugs.com - Pharma News - March 15, 2022 Category: Pharmaceuticals Source Type: news
Adults With Asthma Compliant With COVID-19 Mask Wearing
THURSDAY, Feb. 3, 2022 -- Adults with asthma report being compliant with COVID-19-related masking, despite some problematic effects, according to a study published in the January issue of the Journal of Allergy and Clinical Immunology: In...
Source: Drugs.com - Pharma News - February 3, 2022 Category: Pharmaceuticals Source Type: news
Assessment of COVID-19 vaccines acceptance in the Lebanese population: a national cross-sectional study
ConclusionsOur findings support the need to improve knowledge about COVID-19 infection and vaccination through education and awareness programs. Specifically residents of rural areas should be targeted to optimize COVID-19 vaccine acceptance among the Lebanese population.
Source: Journal of Pharmaceutical Policy and Practice - January 11, 2022 Category: Pharmaceuticals Source Type: research
Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine
NEW BRUNSWICK, N.J., December 15, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for use of the Company’s COVID-19 vaccine as a booster for adults aged 18 and older at least two months after primary vaccination with a single-shot of the Johnson & Johnson COVID-19 vaccine, and as a ‘mix and match’ booster following primary vaccination with an approved two-shot mRNA COVID-19 vaccine regimen (known as heterologous boosting). “We are pleased with today’s Positiv...
Source: Johnson and Johnson - December 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Statement on Data Published in PLOS Medicine on Tolerability and Immune Response of Johnson & Johnson Ebola Vaccine Regimen in Adults Living with HIV
NEW BRUNSWICK, N.J., October 29, 2021 – Data published in PLOS Medicine demonstrated that the Johnson & Johnson (the Company) Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), was well tolerated and induced a robust immune response in both healthy adults and adults living with HIV. These findings, alongside Phase 3 data recently published in The Lancet Infectious Diseases, support the potential prophylactic use of the vaccine regimen to protect people at risk of acquiring Ebola. The regimen was granted Marketing Authorisation by the European Commission in July 2020 and Prequalification from th...
Source: Johnson and Johnson - October 29, 2021 Category: Pharmaceuticals Source Type: news
